PCSK9 and Myalgia: In contrast to some findings from RCTs and systematic reviews of RCTs that have shown no significant difference in serious events such as myalgia between patients treated with PCSK9 inhibitors and control participants,34, 35 accumulating studies have detected a risk of musculoskeletal adverse events (MAEs) associated with PCSK9 inhibitors.36, 37, 38, 39